• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Streamex Corp.

    10/3/25 5:25:11 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on October 3, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   26-4333375
    (State or other jurisdiction   (I.R.S. Employer
    of incorporation or organization)   Identification No.)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

    (Address of Principal Executive Offices) (Zip Code)

     

    Streamex Corp. 2023 Long-Term Incentive Plan, as amended

    (Full title of the plan)

     

    Karl Henry McPhie

    Chief Executive Officer

    Streamex Corp.

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

    (Name and address of agent for service)

     

    (203) 409-5444

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Gregory Sichenzia, Esq.

    Avital Perlman, Esq.

    Barrett DiPaolo, Esq.

    Sichenzia Ross Ference Carmel LLP

    1185 Avenue of the Americas, 31st Floor

    New York, NY 10036

    (212) 930-9700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANTORY NOTE

     

    Streamex Corp. (f/k/a/ BioSig Technologies, Inc.), a Delaware corporation (the “Company”) is filing this registration statement with the Securities and Exchange Commission (the “SEC”) to register the sale and issuance of up to 10,359,211 additional shares of the Company’s common stock, par value $0. 001 per share (“Common Stock”), authorized for issuance pursuant to awards under the Company’s 2023 Long-Term Incentive Plan (the “Plan”), pursuant to the provisions of the Plan providing for an increase in the number of shares of Common Stock reserved and available for issuance under the Plan. The Company previously registered the sale of shares of Common Stock under the Plan on a registration statement on Form S-8 filed with the SEC on January 13, 2025 (File No. 333-284255) (the “Prior Registration Statement”).

     

    Pursuant to General Instruction E to Form S-8, this registration statement hereby incorporates by reference the contents of the Prior Registration Statement except as set forth below.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.

     

    Not required to be filed with this Registration Statement.

     

    Item 2. Registrant Information and Employee Plan Annual Information.

     

    Not required to be filed with this Registration Statement.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Commission, are incorporated in this Registration Statement by reference:

     

    ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on April 15, 2025;

     

    ● All other reports filed by the Registrant with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Annual Report on Form 10-K referred to in (a) above; and

     

    ● the description of the Company’s common stock and warrants contained in the Form 8-A filed with the SEC on September 17, 2018, as amended by Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including any amendments thereto or reports filed for the purposes of updating this description.

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed report or document which also is incorporated or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Set forth below is a description of certain provisions of the Company’s Amended and Restated Certificate of Incorporation, as amended to date (the “Certificate of Incorporation”) and Amended and Restated Bylaws, as amended to date (the “Bylaws”), and the Delaware General Corporation Law (the “DGCL”). This description is intended as a summary only and is qualified in its entirety by reference to the Certificate of Incorporation, the Bylaws and the DGCL.

     

    Article IX of the Certificate of Incorporation limits the personal liability of directors to the Company or the Company’s stockholders for monetary damages for acts or omissions occurring in their capacity as directors, to the fully extent permitted by the laws of the State of Delaware and any other applicable law, as such laws currently exist and to such greater extent as they may provide in the future.

     

    Section 145 of the DGCL provides, in general, that a corporation incorporated under the laws of the State of Delaware, as we are, may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. In the case of a derivative action, a Delaware corporation may indemnify any such person against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification will be made in respect of any claim, issue or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or any other court in which such action was brought determines such person is fairly and reasonably entitled to indemnity for such expenses.

     

    The Certificate of Incorporation and Bylaws provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions of the DGCL, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders’ or directors’ resolution or by contract. Any repeal or modification of these provisions approved by our stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification.

     

    We are also permitted to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his actions, whether or not the DGCL would permit indemnification.

     

     

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit

    Number

      Description
       
    4.1   Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form S-1 filed on July 22, 2013)
    4.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.2 to the Form S-1 filed on July 22, 2013)
    4.3   Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.3 to the Form S-1 filed on July 22, 2013)
    4.4   Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.5 to the Form S-1/A filed on January 21, 2014)
    4.5   Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.6 to the Form S-1/A filed on March 28, 2014)
    4.6   Certificate of Fifth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on August 21, 2014)
    4.7   Certificate of Sixth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 25, 2016)
    4.8   Certificate of Seventh Amendment to the Amended and Restated Certificate of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 10, 2018)
    4.9   Certificate of Amendment of Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc., dated January 31, 2024 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on January 31, 2024)
    4.10   Ninth Certificate of Amendment (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 5, 2025)
    4.11   Certificate of Amendment of Amended And Restated Certificate Of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 11, 2025)
    4.13   Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to the Exhibit 3.1 to the Form 8-K filed on September 27, 2019)
    4.14   Amendment No. 1 to Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on October 22, 2019)
    4.15   Amendment No. 2 to Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on December 28, 2022)
    4.16   Amendment No. 3 to the Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 8, 2023)
    4.17   BioSig Technologies, Inc. 2023 Long-Term Incentive Plan dated February 7, 2023 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on February 9, 2023)
    4.18   BioSig Technologies, Inc. First Amendment to the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 18, 2023)
    4.19   BioSig Technologies, Inc. Second Amendment to the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 31, 2024)
    4.20   Incentive Plan Amendment (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on September 5, 2025)
    5.1   Legal Opinion of Sichenzia Ross Ference Carmel LLP*
    23.1   Consent of Marcum LLP, independent registered public accounting firm*
    23.2   Consent of Sichenzia Ross Ference Carmel LLP (incorporated in Exhibit 5.1)*
    24.1   Powers of Attorney (included on the signature page to this Registration Statement)*
    107   Filing Fee Table*

     

    * Filed herewith.

     

     

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
         
      (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;
         
      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
       
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the in the City of Winter Park, State of Florida, on October 3, 2025.

     

      Streamex Corp.
         
      By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Karl Henry McPhie and Ferdinand Groenewald, and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Streamex Corp. and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    * * * *

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             
    /s/ Anthony Amato   Director   October 3, 2025
    Anthony Amato        
             
    /s/ Ferdinand Groenewald   Chief Financial Officer   October 3, 2025
    Ferdinand Groenewald   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Christopher A. Baer   Director   October 3, 2025
    Christopher A. Baer        
             
    /s/ Donald F. Browne   Director   October 3, 2025
    Donald F. Browne        
             
    /s/ Karl Henry McPhie   Chief Executive Officer, Director (Principal Executive officer)   October 3, 2025
    Karl Henry McPhie        
             
    /s/ Morgan Lekstrom   Chairman   October 3, 2025
    Morgan Lekstrom        
             
    /s/ Steven Abelman   Director   October 3, 2025
    Steven Abelman        

     

     

     

     

    Get the next $STEX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STEX
    SEC Filings

    View All

    SEC Form S-8 filed by Streamex Corp.

    S-8 - Streamex Corp. (0001530766) (Filer)

    10/3/25 5:25:11 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. to Participate in the Clear Street Disruptive Technology Conference on November 19-20, 2025

    LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets, today announced the executive management team, will participate in one-to-one meetings at the Clear Street Disruptive Technology Conference at The Four Seasons Resort in Palm Beach, Florida, taking place November 19-20, 2025. "This conference represents an ideal platform to connect with institutional investors who understand that the transformative potential of real-world asset tokenization is a key innovation," said Henry McPhie, CEO and Co-Founder of Streamex Corp. About Streamex Corp.Streamex is a real-world ass

    9/29/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs

    Key Partnership Highlights: Streamex & Simplify have entered into a letter of intent outlining a framework for pursuing a strategic partnership to leverage each other's platforms for next-generation financial products.Focus on the integration of Streamex's tokenized yield-bearing gold into ETF structures, bridging blockchain innovation with institutional-grade financial products.Distribution expansion across both partners' platforms, subject to definitive agreements and regulatory approval.Jointly intending to collaborate, subject to definitive agreements, on developing ETP/ETF offerings designed to expand investor access to regulated, liquid, and yield-generating gold and commodity-backed

    9/17/25 8:30:00 AM ET
    $BSGM
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care